Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Future Journal of Pharmaceutical Sciences Pub Date : 2024-12-18 DOI:10.1186/s43094-024-00751-w

Marwa M. Saeed

{"title":"Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration","authors":"Marwa M. Saeed","doi":"10.1186/s43094-024-00751-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Several researches describe Alzheimer’s disease (AD) as Type-III diabetes mellitus due to shared pathophysiological mechanisms between AD and DM and the fact that one disease can increase the incidence of the other. Therefore, keeping glucose level under control protects the brain from its harmful effects and delays the incidence of AD in susceptible individuals by using anti-diabetic agents. Several anti-diabetic classes were explored for their protective effect against AD, among them that attracted more attention was sodium–glucose cotransporter inhibitor dapagliflozin (DAPA).</p><h3>Main body of the abstract</h3><p>This review aims at illustrating various protective mechanisms that DAPA proved to exert on cognition and memory. DAPA showed promising results by its influence on behavioral parameters highlighted enhancement of both spatial and non-spatial learning and memory, in addition to ameliorating associated anxiety by its effect on various neurotransmitters. DAPA succeeded in promoting neurogenesis, synaptic plasticity, and synaptic density, and managed to demonstrate anti-inflammatory, antioxidant, and antiapoptotic properties. Moreover, DAPA enhanced the activity of mitochondria and promoted autophagy, in addition to its impact on the PI3K/AKT/mTOR and Wnt/β-catenin signaling pathways.</p><h3>Short conclusion</h3><p>DAPA showed promising results in different AD models to enhance memory and improve cognitive deficits.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00751-w","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-024-00751-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Several researches describe Alzheimer’s disease (AD) as Type-III diabetes mellitus due to shared pathophysiological mechanisms between AD and DM and the fact that one disease can increase the incidence of the other. Therefore, keeping glucose level under control protects the brain from its harmful effects and delays the incidence of AD in susceptible individuals by using anti-diabetic agents. Several anti-diabetic classes were explored for their protective effect against AD, among them that attracted more attention was sodium–glucose cotransporter inhibitor dapagliflozin (DAPA).

Main body of the abstract

This review aims at illustrating various protective mechanisms that DAPA proved to exert on cognition and memory. DAPA showed promising results by its influence on behavioral parameters highlighted enhancement of both spatial and non-spatial learning and memory, in addition to ameliorating associated anxiety by its effect on various neurotransmitters. DAPA succeeded in promoting neurogenesis, synaptic plasticity, and synaptic density, and managed to demonstrate anti-inflammatory, antioxidant, and antiapoptotic properties. Moreover, DAPA enhanced the activity of mitochondria and promoted autophagy, in addition to its impact on the PI3K/AKT/mTOR and Wnt/β-catenin signaling pathways.

Short conclusion

DAPA showed promising results in different AD models to enhance memory and improve cognitive deficits.

Graphical abstract

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

23 weeks

期刊介绍： Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.